Observational Study on GUselkumab: Effectiveness and Impact on quaLity of LIfe in naïVE or Bio Experienced Patients With Regional (Facial and Genital) Psoriasis (GULLIVER Study)
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms GULLIVER
- Sponsors Janssen-Cilag
- 03 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Nov 2023.